2b7d: Difference between revisions

Line 1:

[[Image:2b7d.~~gif~~|left|200px]]

[[Image:2b7d.png|left|200px]]

<!--

Line 9:

Line 10:

~~'''~~Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model~~'''~~

===Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model===

~~==Overview==~~

<!--

~~Highly selective and potent factor VIIa~~-~~tissue factor (fVIIa.TF) complex inhibitors were generated through structure~~-~~based design.~~ The ~~pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species~~, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, ~~and a pharmacodynamic concentration-response model was developed~~ to ~~describe~~ the ~~platelet deposition data~~. ~~Results for heparin and enoxaparin (Lovenox~~) in the ~~baboon model are also presented~~.

The line below this paragraph, {{ABSTRACT_PUBMED_16412633}}, adds the Publication Abstract to the page

(as it appears on PubMed at http://www.pubmed.gov), where 16412633 is the PubMed ID number.

-->

==Disease==

Line 44:

Line 48:

[[Category: Yu, C.]]

[[Category: Short hydrogen bond]]

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Sat May 3 19~~:56:48 2008''

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 01:58:28 2008''

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-[[Image:2b7d.gif|left|200px]]
+{{Seed}}
+[[Image:2b7d.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2b7d|  PDB=2b7d  |  SCENE=  }}
-'''Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model'''
+===Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model===
-==Overview==
+<!--
-Highly selective and potent factor VIIa-tissue factor (fVIIa.TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, and a pharmacodynamic concentration-response model was developed to describe the platelet deposition data. Results for heparin and enoxaparin (Lovenox) in the baboon model are also presented.
+The line below this paragraph, {{ABSTRACT_PUBMED_16412633}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 16412633 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_16412633}}
 ==Disease==
@@ Line 44: / Line 48: @@
 [[Category: Yu, C.]]
 [[Category: Short hydrogen bond]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 19:56:48 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 01:58:28 2008''